Targeting Cellular Pseudo-Senescence to Overcome PARP inhibitors Resistance in BRCA1-Mutated Breast Cancer
Preprint
Abstract
Poly (ADP-ribose) polymerase (PARP) inhibitors (PARPi) are a mainstay therapy for homologous recombination (HR)-deficient cancers; however, resistance remains a major clinical challenge. Previously, through a genome wide CRISPR screen, we identified ZNF251 haploinsufficiency as a novel driver of PARPi resistance. In BRCA1-mutant (BRCA1mut) cells, ZNF251 deficiency led to HR hyperactivation, conferring PARPi resistance that could be reversed by RAD51 inhibition. In this study, we further show that ZNF251 deficiency induces replication stress and a pseudo-senescence state, in which cells exhibit molecular and phenotypic markers of senescence while retaining proliferative capacity. Because senomorphic and senolytic therapies can target senescent cells, we tested whether these approaches could overcome PARPi resistance in ZNF251-deficient breast cancer cells. Critically, targeting this senescence-like state with either senomorphic agents, such as cytokine inhibitors, or senolytic agents, such as BCL-2 and BCL-XL inhibitors, overcame PARPi resistance ex vivo and in vivo. Importantly, pseudo-senescence was also observed in other PARPi-resistant contexts driven by HR hyperactivation, including 53BP1- and Shieldin-mutant cells, suggesting that it may represent a broader mechanism underlying PARPi resistance in breast cancer. Furthermore, in two olaparib-resistant, BRCA-mutant triple-negative breast cancer organoid models, treatment with DT2216, a BCL-XL targeting PROTAC, sensitized both models to olaparib. Together, our work defines a novel pathway linking HR hyperactivation, replication stress, and pseudo-senescence, and positions both senomorphic and senolytic therapies as promising strategies to overcome PARPi resistance in BRCA1mut breast cancer.Keywords
This publication has 36 references indexed in Scilit:
- ZNF251 haploinsufficiency confers PARP inhibitors resistance in BRCA1-mutated cancer cells through activation of homologous recombinationCancer Letters, 2025
- An Overview of PARP Inhibitors for the Treatment of Breast CancerTargeted Oncology, 2021
- Discovery of A-1331852, a First-in-Class, Potent, and Orally-Bioavailable BCL-XL InhibitorACS Medicinal Chemistry Letters, 2020
- Cellular Senescence: Defining a Path ForwardCell, 2019
- PARP Inhibitor Resistance: A Tug-of-War in BRCA-Mutated CellsTrends in Cell Biology, 2019
- Erratum: Unexplored therapeutic opportunities in the human genomeNature Reviews Drug Discovery, 2018
- Cellular Senescence: A Translational PerspectiveEBioMedicine, 2017
- Senescence in Health and DiseaseCell, 2017
- Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activityThe Lancet Oncology, 2010
- An inhibitor of Bcl-2 family proteins induces regression of solid tumoursNature, 2005